DERM Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
DERM is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock has weak price action, bearish moving averages, a recent sharp selloff, and negative news flow tied to a securities-fraud investigation. While revenue growth and analyst optimism are positives, the current setup is too uncertain to justify an immediate long-term buy. If the investor is unwilling to wait, this is still not an attractive entry.
Price is 4.995, slightly below the prior close of 5.00 and still below the pivot at 5.131. The trend is weak: SMA_200 > SMA_20 > SMA_5 indicates a bearish structure, even though the MACD histogram is positive at 0.0714 and contracting, which suggests downside momentum may be easing. RSI_6 at 37.218 is neutral-to-weak and does not confirm a strong rebound. Key levels: support at 4.924 and 4.797, resistance at 5.337 and 5.464. Overall, the chart shows a weak recovery attempt inside a broader bearish trend.
["Analyst B. Riley raised the price target to $12 from $11 and kept a Buy rating.", "Q4 revenue grew 18.05% YoY to $16.079M.", "Gross margin improved to 59.54%, up 1.88% YoY.", "Emrosi prescription volumes reportedly grew about 50% sequentially, supporting future growth potential.", "MACD histogram is slightly positive, suggesting the selloff may be losing momentum."]
["Pomerantz LLP is investigating the company for potential securities fraud or unlawful business practices.", "The stock fell 30.01% after the earnings report, showing poor market reaction.", "Net income worsened to -$1.247M and EPS fell to -0.05 in Q4.", "Bearish moving average alignment remains in place.", "Options positioning is bearish with a 1.98 put-call ratio.", "No recent hedge fund, insider, congress, AI Stock Picker, or SwingMax support signal."]
Latest quarter: Q4 2025. Revenue increased 18.05% YoY to $16.08M, which is a solid top-line growth rate. Gross margin improved to 59.54%, showing better product economics. However, profitability weakened materially: net income fell to -$1.247M and EPS dropped to -$0.05. The company is growing, but earnings quality and bottom-line performance remain weak.
Analyst sentiment is positive on the surface. B. Riley raised its price target from $11 to $12 and maintained a Buy rating, citing strong Q4 execution, Emrosi revenue of $14.7M in FY25 over nine months, and roughly 50% sequential prescription growth. This is the main bullish Wall Street view. The bearish side is that the stock has already sold off sharply and current price action does not reflect that optimism yet.
